Communicable Diseases  >>  tenofovir disoproxil fumarate  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tenofovir disoproxil fumarate / Generic mfg.
NCT01489046 / 2011-003329-89: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Terminated
2b
297
US, Canada, Europe, RoW
BMS-986001, Placebo matching with BMS-986001, Efavirenz, Sustiva®, Lamivudine, Epivir®, Tenofovir, Viread®
Bristol-Myers Squibb
HIV-1 Infection
03/13
07/14
NCT01737359: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

Terminated
2a
2
RoW
amdoxovir 300 mg bid, DAPD, AMDX, amdoxovir 500 mg bid, tenofovir DF 300 mg qd, Viread
RFS Pharma, LLC
Human Immunodeficiency Virus Infection
02/13
03/13
NCT00046033: Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed
2
118
US
Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
03/03
 
NCT00350272: Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed
2
76
US
Elvucitabine, ACH-126,443, Lamivudine, 3TC, Tenofovir, Viread, Efavirenz, Sustiva
Alexion, Achillion, a wholly owned subsidiary of Alexion
HIV Infections
08/07
04/09
NCT00119379: Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

Completed
2
50
US
NucleomaxX, uridine, Tenofovir Disoproxil Fumarate, TDF
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
10/08
10/08
NCT00131677: Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

Completed
2
400
US
tenofovir disoproxil fumarate, Viread, placebo
Centers for Disease Control and Prevention, San Francisco Department of Public Health, AIDS Research Consortium of Atlanta
HIV Infection
08/09
08/09
NCT00896051 / 2009-010887-41: TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Completed
2
50
US, Europe, RoW
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Janssen R&D Ireland
HIV Infections, Acquired Immunodeficiency Syndrome
04/12
04/12
NCT01334567: Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan

Completed
2
30
RoW
Tenofovir DF, Viread®
Gilead Sciences
Hepatitis B
12/13
12/13
NCT01903031: Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

Completed
2
84
US, RoW
Nuvaring, Etonogestrel/ethinyl estradiol vaginal ring, EFV, Efavirenz, ATV/r, Atazanavir/Ritonavir, TDF, Tenofovir Disoproxil Fumarate, NRTIs, Nucleoside Reverse Transcriptase Inhibitor
AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
10/16
10/16
NCT02452528: Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated
2
4
US
ARC-520, Placebo, Entecavir, Baraclude, Tenofovir, Viread, diphenhydramine
Arrowhead Pharmaceuticals
Chronic Hepatitis B
12/16
12/16
Monarch, NCT02577029 / 2015-005499-46: Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

Terminated
2
79
Europe, RoW
ARC-520, entecavir, Baraclude, pegylated interferon alpha 2a, Peginterferon, Pegasys, tenofovir disoproxil, Viread, antihistamine
Arrowhead Pharmaceuticals
Hepatitis B, Hepatitis D
12/16
12/16
HIDIT-II, NCT00932971 / 2008-005560-13: HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis

Completed
2
70
Europe
PEG-IFN alfa-2a, Tenofovir, Pegasys, Viread, PEG-IFN alfa-2a, placebo
HepNet Study House, German Liverfoundation, Hannover Medical School, Hoffmann-La Roche, Gilead Sciences
Hepatitis D
08/17
08/17
NCT03109730: Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Completed
1b/2a
38
Europe, RoW
ABI-H0731, Placebo for ABI-H0731, Entecavir, ETV, Tenofovir Disoproxil Fumarate, TDF, Pegasys, peginterferon alfa-2a
Assembly Biosciences
Chronic Hepatitis B
03/18
06/18

Download Options